Antidiuresis: a new concept in managing female daytime urinary incontinence.

What Was Tested

Researchers studied Deamino Arginine Vasopressin in this randomized controlled trial publication.

Who Took Part

According to the abstract, 60 women were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, women only.

A multicentre, multinational, randomized, double-blind, placebo-controlled, cross-over exploratory study of women (aged 18-80 years) complaining of severe daytime urinary incontinence was conducted in three centres (King's College Hospital; Boras County Hospital and Skejby Hospital).

Seventy-five patients were screened of whom 64 were randomized.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled, crossover and multicenter.

Because people in this Deamino Arginine Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Deamino Arginine Vasopressin study, the assignments were hidden from both participants and investigators until the end.

Some women received a placebo instead of Deamino Arginine Vasopressin, giving a reference point.

In the crossover set-up each of the women took both Deamino Arginine Vasopressin and the comparison in turn, acting as their own control.

In all, 60 women received study medication (safety population) and 57 completed the study.

The intention-to-treat population comprised 59 patients and there were 41 in the per protocol analysis.

Women were instructed to take the drug at a time of their choosing, but >/= 4 h before bedtime.

What Was Measured

PubMed files the paper under topics including Deamino Arginine Vasopressin, Renal Agents and Urinary Incontinence.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Deamino Arginine Vasopressin in 60 women.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2004 (BJU international), a journal based in England.

More context: all human trials.